141 related articles for article (PubMed ID: 7826911)
1. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
Orlandi F; Caraci P; Berruti A; Puligheddu B; Pivano G; Dogliotti L; Angeli A
Ann Oncol; 1994 Oct; 5(8):763-5. PubMed ID: 7826911
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine.
Wu LT; Averbuch SD; Ball DW; de Bustros A; Baylin SB; McGuire WP
Cancer; 1994 Jan; 73(2):432-6. PubMed ID: 8293411
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
Schlumberger M; Abdelmoumene N; Delisle MJ; Couette JE
Br J Cancer; 1995 Feb; 71(2):363-5. PubMed ID: 7530987
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).
Nocera M; Baudin E; Pellegriti G; Cailleux AF; Mechelany-Corone C; Schlumberger M
Br J Cancer; 2000 Sep; 83(6):715-8. PubMed ID: 10952773
[TBL] [Abstract][Full Text] [Related]
5. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil.
Petursson SR
Cancer; 1988 Nov; 62(9):1899-903. PubMed ID: 3167804
[TBL] [Abstract][Full Text] [Related]
6. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.
Bajetta E; Rimassa L; Carnaghi C; Seregni E; Ferrari L; Di Bartolomeo M; Regalia E; Cassata A; Procopio G; Mariani L
Cancer; 1998 Jul; 83(2):372-8. PubMed ID: 9669822
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.
Di Bartolomeo M; Bajetta E; Bochicchio AM; Carnaghi C; Somma L; Mazzaferro V; Visini M; Gebbia V; Tumolo S; Ballatore P
Ann Oncol; 1995 Jan; 6(1):77-9. PubMed ID: 7710986
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience.
Deutschbein T; Matuszczyk A; Moeller LC; Unger N; Yuece A; Lahner H; Mann K; Petersenn S
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):540-3. PubMed ID: 21667440
[TBL] [Abstract][Full Text] [Related]
11. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
Stein R; Chen S; Reed L; Richel H; Goldenberg DM
Cancer; 2002 Jan; 94(1):51-61. PubMed ID: 11815960
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial.
Ollivier S; Fonck M; Bécouarn Y; Brunet R
Am J Clin Oncol; 1998 Jun; 21(3):237-40. PubMed ID: 9626788
[TBL] [Abstract][Full Text] [Related]
13. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Iop A; Cartei G; Vigevani E; Clocchiatti L; Mansutti M; Sibau AM
Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
[TBL] [Abstract][Full Text] [Related]
15. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
Stein R; Goldenberg DM
Mol Cancer Ther; 2004 Dec; 3(12):1559-64. PubMed ID: 15634649
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]